Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRXGet Free Report) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,070,000 shares, an increase of 13.1% from the February 29th total of 1,830,000 shares. Approximately 1.9% of the company’s shares are short sold. Based on an average daily trading volume, of 1,460,000 shares, the short-interest ratio is currently 1.4 days.

Amneal Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:AMRX opened at $6.06 on Monday. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -19.55 and a beta of 1.32. Amneal Pharmaceuticals has a 1-year low of $1.26 and a 1-year high of $6.46. The company’s fifty day moving average is $5.66 and its two-hundred day moving average is $4.99. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63.

Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) last issued its quarterly earnings data on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. The firm had revenue of $616.98 million for the quarter, compared to the consensus estimate of $630.67 million. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.5 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on AMRX. The Goldman Sachs Group upped their price target on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research report on Monday, March 4th. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 4th. Barclays upped their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. Finally, Piper Sandler upped their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $7.31.

Read Our Latest Report on AMRX

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. American Century Companies Inc. increased its holdings in Amneal Pharmaceuticals by 43.2% in the 1st quarter. American Century Companies Inc. now owns 21,715 shares of the company’s stock valued at $30,000 after buying an additional 6,549 shares during the period. Engineers Gate Manager LP bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth about $34,000. Tower Research Capital LLC TRC grew its holdings in shares of Amneal Pharmaceuticals by 120.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,165 shares of the company’s stock worth $35,000 after purchasing an additional 6,089 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth about $35,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth about $38,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Further Reading

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.